Brad Smith is listed as an executive officer and director on 2 SEC Form D filings by 2 issuers between Aug 2017 and Feb 2024: eGenesis, Inc. (Cambridge, MA — biotechnology — 2024; $125M reported sold to 43 investors) and Homology Medicines, Inc. (Bedford, MA — pharmaceuticals — 2017; $83.5M reported sold to 19 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 7 years. Across those companies the filings report $208.5M sold in total.
Listed alongside Steven Gillis (2 shared filings), Albert Seymour (1 shared filing), Albert Wiegman (1 shared filing), Arthur Tzianabos (1 shared filing), Cameron Wheeler (1 shared filing) and 13 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Brad. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AZ, CA, DE, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 2 public filings for Brad Smith and found 6 differences: No amendment in the last 12 months on an offering that may still be open; Same name, different state: "Brad Smith" (TN) is a separate record; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.